Related Experiment Videos
Microglial in neurodegenerative disorders: emphasis on Alzheimer's disease
A McRae1, A Dahlström, E A Ling
1Institute of Anatomy and Cell Biology, University of Göteborg, Sweden.
Abstract:
Hallmark lesions of Alzheimer's disease (AD) are filled with reactive immunocompetent microglia, suggesting that immunological aberrations may participate in the pathophysiology of this disorder. If immune-mediated processes are closely linked to neuronal breakdown it would be of importance to have a reliable means to detect these processes. Cerebrospinal fluid microglial antibodies found mainly in AD patients are discussed as such potential sources. These antibodies recognize microglia in the developing rat brain, in neuronal cultures and on AD cortical biopsies. Treatment aimed at downregulating microglial is discussed and may have therapeutic significance for AD patients. Largely this review presents current opinions which support the concept that inflammation and similar immune mechanisms need to be considered as participating in AD pathogenesis.
Insights
Alzheimer's disease (AD) involves immune system changes, with microglia antibodies in cerebrospinal fluid potentially aiding diagnosis. Targeting these immune responses may offer new therapeutic strategies for AD.
Area of Science:
- Neuroimmunology
- Pathophysiology of Alzheimer's disease
Background:
- Alzheimer's disease (AD) hallmark lesions contain reactive microglia, indicating a role for immune system aberrations.
- Immune-mediated processes may be closely linked to neurodegeneration in AD.
- A reliable method to detect these immune processes is crucial for understanding AD.
Purpose of the Study:
- To explore cerebrospinal fluid (CSF) microglial antibodies as potential diagnostic markers for AD.
- To review the role of neuroinflammation in Alzheimer's disease pathogenesis.
- To discuss potential therapeutic strategies targeting microglial activity in AD.
Main Methods:
- Review of current literature on microglial antibodies in CSF.
- Analysis of antibody recognition in developing rat brain, neuronal cultures, and AD cortical biopsies.
- Discussion of immunomodulatory treatments for AD.
Main Results:
- Microglial antibodies are predominantly found in CSF of AD patients.
- These antibodies recognize microglia across different biological systems, including human AD tissue.
- Evidence suggests a significant involvement of inflammation and immune mechanisms in AD pathogenesis.
Conclusions:
- CSF microglial antibodies show promise as biomarkers for Alzheimer's disease.
- Targeting microglial-driven inflammation represents a potential therapeutic avenue for AD.
- Immune mechanisms are integral to the understanding and treatment of Alzheimer's disease.